CAMBRIDGE, England, Nov. 26, 2013 /CNW/ - Cytocell Ltd. announced the
availability of a new range of in vitro diagnostic tests to aid in detecting patients with Chronic Lymphocytic
Leukaemia (CLL), a cancer of the lymphocytes.
(Logo: http://photos.prnewswire.com/prnh/20120906/559436 )
The new range of Cytocell CLL FISH probes includes the new CLL PROFILER
Kit comprising of the P53/ATM Probe Combination and a newly developed
D13S319/13qter/12cen Deletion/Enumeration probe. In total Cytocell has
19 different FISH probes specifically designed with the intention of
detecting abnormalities of the most common genes linked with CLL.
CLL is the most common form of leukaemia in the U.S. and Europe and is
most commonly found in Caucasian men 60 years and older. In the United
States, more than 15,000 patients are diagnosed with CLL each year,
many of whom are discovered during routine medical exams. CLL
progresses more slowly than other types of leukaemia and most patients
diagnosed with CLL have early-stage disease. Up to 50 percent are at
risk for accelerated progression while others live for many years and
often do not require therapy.
Cytocell's Aquarius® CLL PROFILER kit detects cytogenetic abnormalities in bone marrow
specimens and peripheral blood samples from patients with CLL.
Deletions of ATM and TP53 are the most serious rearrangements involved
in CLL and detection of deletions of these genes provides very
important information as to the therapy choices for such patients,
especially since deletions of TP53 and ATM provide a poor prognosis.
"These new additions to our catalogue augments our already extensive
collection of FISH probes for leukaemia and provides comprehensive
solution to the diagnosis of CLL," said Dr Martin Lawrie, Managing Director of Cytocell. "The launch of this product demonstrates our continued focus on our
range of Haematology probes which is continually growing. We also
believe that through our Custom FISH probe service, myProbes, we will
be able to offer more and more of such products for Haematology, driven
by the clinical requirements of our customers."
Chromosomal abnormalities have been shown to play a major role in
disease evolution in several haematological malignancies. Fluorescence In Situ Hybridisation (FISH), using locus-specific probes, which are capable of
defining numerical and structural chromosome changes, has now become a
routine diagnostic test in the clinical laboratory and the technique
has thus been shown to be useful in the management of cancer patients.
About Cytocell Ltd.
Cytocell is a leading European developer and manufacturer of FISH probes
for use in both routine cytogenetics and in the analysis and
classification of Cancers. The Company's products are well established
in Cytogenetics as the Company is celebrating its 20th year of supplying them to this market. More recently, the Company has
focused on developing products for Oncology and now has a catalogue of
some 350 products for Cytogenetics, Haematology and Solid Tumour
analysis as well as developing custom FISH probes for customers with
specific interests under the myProbes® brand. Cytocell's products are available through a well established
distributor network, covering more than 60 countries worldwide.
Cytocell's FISH probe service is currently proving to be invaluable to
cancer researchers and clinicians worldwide.
Cytocell's news releases and other information are available on the
company's Web site at http://www.cytocell.com.
SOURCE: Cytocell Ltd
For further information:
Sales & Marketing Director